Institution
Tulane University
Education•New Orleans, Louisiana, United States•
About: Tulane University is a education organization based out in New Orleans, Louisiana, United States. It is known for research contribution in the topics: Population & Blood pressure. The organization has 24478 authors who have published 47205 publications receiving 1944993 citations. The organization is also known as: University of Louisiana.
Topics: Population, Blood pressure, Receptor, Poison control, Medicine
Papers published on a yearly basis
Papers
More filters
••
TL;DR: SAGEA is frequently present in poorly performing first-grade students in whom it adversely affects learning performance and the data suggest that a subset of children with behavioral and learning disabilities could have SAGEA and may benefit from prospective medical evaluation and treatment.
Abstract: Objective. To assess the impact of sleep-associated gas exchange abnormalities (SAGEA) on school academic performance in children. Design. Prospective study. Setting. Urban public elementary schools. Participants. Two hundred ninety-seven first-grade children whose school performance was in the lowest 10th percentile of their class ranking. Methods. Children were screened for obstructive sleep apnea syndrome at home using a detailed parental questionnaire and a single night recording of pulse oximetry and transcutaneous partial pressure of carbon dioxide. If SAGEA was diagnosed, parents were encouraged to seek medical intervention for SAGEA. School grades of all participating children for the school year preceding and after the overnight study were obtained. Results. SAGEA was identified in 54 children (18.1%). Of these, 24 underwent surgical tonsillectomy and adenoidectomy (TR), whereas in the remaining 30 children, parents elected not to seek any therapeutic intervention (NT). Overall mean grades during the second grade increased from 2.43 ± 0.17 (SEM) to 2.87 ± 0.19 in TR, although no significant changes occurred in NT (2.44 ± 0.13 to 2.46 ± 0.15). Similarly, no academic improvements occurred in children without SAGEA. Conclusions. SAGEA is frequently present in poorly performing first-grade students in whom it adversely affects learning performance. The data suggest that a subset of children with behavioral and learning disabilities could have SAGEA and may benefit from prospective medical evaluation and treatment.
1,117 citations
••
TL;DR: Reduced sodium intake and weight loss constitute a feasible, effective, and safe nonpharmacologic therapy of hypertension in older persons.
Abstract: Context.—Nonpharmacologic interventions are frequently recommended for treatment
of hypertension in the elderly, but there is a paucity of evidence from randomized
controlled trials in support of this recommendation.Objective.—To determine whether weight loss or reduced sodium intake is effective
in the treatment of older persons with hypertension.Design.—Randomized controlled trial.Participants.—A total of 875 men and women aged 60 to 80 years with systolic blood
pressure lower than 145 mm Hg and diastolic blood pressure lower than 85 mm
Hg while receiving treatment with a single antihypertensive medication.Setting.—Four academic health centers.Intervention.—The 585 obese participants were randomized to reduced sodium intake,
weight loss, both, or usual care, and the 390 nonobese participants were randomized
to reduced sodium intake or usual care. Withdrawal of antihypertensive medication
was attempted after 3 months of intervention.Main Outcome Measure.—Diagnosis of high blood pressure at 1 or more follow-up visits, or treatment
with antihypertensive medication, or a cardiovascular event during follow-up
(range, 15-36 months; median, 29 months).Results.—The combined outcome measure was less frequent among those assigned
vs not assigned to reduced sodium intake (relative hazard ratio, 0.69; 95%
confidence interval [CI], 0.59-0.81; P<.001) and,
in obese participants, among those assigned vs not assigned to weight loss
(relative hazard ratio, 0.70; 95% CI, 0.57-0.87; P<.001).
Relative to usual care, hazard ratios among the obese participants were 0.60
(95% CI, 0.45-0.80; P<.001) for reduced sodium
intake alone, 0.64 (95% CI, 0.49-0.85; P=.002) for
weight loss alone, and 0.47 (95% CI, 0.35-0.64; P<.001)
for reduced sodium intake and weight loss combined. The frequency of cardiovascular
events during follow-up was similar in each of the 6 treatment groups.Conclusion.—Reduced sodium intake and weight loss constitute a feasible, effective,
and safe nonpharmacologic therapy of hypertension in older persons.
1,115 citations
••
Institute of Cancer Research1, Université Paris-Saclay2, Université de Montréal3, Peter MacCallum Cancer Centre4, University of British Columbia5, Tulane University6, Huntsman Cancer Institute7, Carlos III Health Institute8, University of Franche-Comté9, Radboud University Nijmegen10, AstraZeneca11, Merck & Co.12, Northwestern University13
TL;DR: In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalUTamide or monotherapy.
Abstract: BACKGROUND: Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with prostate and other cancers. METHODS: We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). All the men had a qualifying alteration in prespecified genes with a direct or indirect role in homologous recombination repair. Cohort A (245 patients) had at least one alteration in BRCA1, BRCA2, or ATM; cohort B (142 patients) had alterations in any of 12 other prespecified genes, prospectively and centrally determined from tumor tissue. Patients were randomly assigned (in a 2:1 ratio) to receive olaparib or the physician's choice of enzalutamide or abiraterone (control). The primary end point was imaging-based progression-free survival in cohort A according to blinded independent central review. RESULTS: In cohort A, imaging-based progression-free survival was significantly longer in the olaparib group than in the control group (median, 7.4 months vs. 3.6 months; hazard ratio for progression or death, 0.34; 95% confidence interval, 0.25 to 0.47; P<0.001); a significant benefit was also observed with respect to the confirmed objective response rate and the time to pain progression. The median overall survival in cohort A was 18.5 months in the olaparib group and 15.1 months in the control group; 81% of the patients in the control group who had progression crossed over to receive olaparib. A significant benefit for olaparib was also seen for imaging-based progression-free survival in the overall population (cohorts A and B). Anemia and nausea were the main toxic effects in patients who received olaparib. CONCLUSIONS: In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recombination repair, olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone. (Funded by AstraZeneca and Merck Sharp & Dohme; PROfound ClinicalTrials.gov number, NCT02987543.).
1,114 citations
••
TL;DR: Exercise 24 hours before the euglycemic clamp increased phosphorylation of insulin receptor and IRS-1 in obese and diabetic subjects but did not increase glucose uptake or PI 3-kinase association with IRS- 1 upon insulin stimulation, which defines a key step in insulin resistance.
Abstract: The broad nature of insulin resistant glucose metabolism in skeletal muscle of patients with type 2 diabetes suggests a defect in the proximal part of the insulin signaling network. We sought to identify the pathways compromised in insulin resistance and to test the effect of moderate exercise on whole-body and cellular insulin action. We conducted euglycemic clamps and muscle biopsies on type 2 diabetic patients, obese nondiabetics and lean controls, with and without a single bout of exercise. Insulin stimulation of the phosphatidylinositol 3-kinase (PI 3-kinase) pathway, as measured by phosphorylation of the insulin receptor and IRS-1 and by IRS protein association with p85 and with PI 3-kinase, was dramatically reduced in obese nondiabetics and virtually absent in type 2 diabetic patients. Insulin stimulation of the MAP kinase pathway was normal in obese and diabetic subjects. Insulin stimulation of glucose-disposal correlated with association of p85 with IRS-1. Exercise 24 hours before the euglycemic clamp increased phosphorylation of insulin receptor and IRS-1 in obese and diabetic subjects but did not increase glucose uptake or PI 3-kinase association with IRS-1 upon insulin stimulation. Thus, insulin resistance differentially affects the PI 3-kinase and MAP kinase signaling pathways, and insulin-stimulated IRS-1-association with PI 3-kinase defines a key step in insulin resistance.
1,106 citations
••
TL;DR: Vascular disease and cancer have become the leading causes of death among Chinese adults and control of hypertension, smoking cessation, increased physical activity, and improved nutrition should be important strategies for reducing the burden of premature death among adults in China.
Abstract: conclusions Vascular disease and cancer have become the leading causes of death among Chinese adults. Our findings suggest that control of hypertension, smoking cessation, increased physical activity, and improved nutrition should be important strategies for reducing the burden of premature death among adults in China.
1,103 citations
Authors
Showing all 24722 results
Name | H-index | Papers | Citations |
---|---|---|---|
Walter C. Willett | 334 | 2399 | 413322 |
JoAnn E. Manson | 270 | 1819 | 258509 |
Frank B. Hu | 250 | 1675 | 253464 |
Eric B. Rimm | 196 | 988 | 147119 |
Krzysztof Matyjaszewski | 169 | 1431 | 128585 |
Nicholas J. White | 161 | 1352 | 104539 |
Tien Yin Wong | 160 | 1880 | 131830 |
Tomas Hökfelt | 158 | 1033 | 95979 |
Thomas E. Starzl | 150 | 1625 | 91704 |
Geoffrey Burnstock | 141 | 1488 | 99525 |
Joseph Sodroski | 138 | 542 | 77070 |
Glenn M. Chertow | 128 | 764 | 82401 |
Darwin J. Prockop | 128 | 576 | 87066 |
Kenneth J. Pienta | 127 | 671 | 64531 |
Charles Taylor | 126 | 741 | 77626 |